Treatment and care advancements in the field of oncology are usually spurred by results of rigorous clinical trials that often employ strict randomization to mitigate biases. However, stakeholders are increasingly recognizing that whilst necessary, clinical trials can fail to capture and emulate true patient heterogeneity and variables seen in real clinical practice.
When and how may real-world data be of value to oncologists? What questions may real-world evidence help answers that clinical trials may not? In an Editorial recently published on our sister site, Oncology Central, Orazio Caffo (Santa Chiara Hospital, Trento, Italy) explores these questions and more.
“…real-world evidence is being increasingly used in the regulatory processes governing drug approvals and in everyday clinical practice. It is now necessary to ensure that real-world studies are carried out under the guidance of precise rules that guarantee the quality of the data on which the evidence is based.”
You may also be interested in: